Abstract 488P
Background
Glioma, the most common malignancy of the central nervous system, is charactarised by its extensive proliferation and invasion. An increasing number of studies suggest that glioma stem cells (GSCs) are at the root of glioma's difficulty in control, treatment and recurrence. The adhesion molecule integrin α2 (ITGA2) plays an important role in regulating various biological behaviors such as cell migration, growth and differentiation. Previous studies have shown that ITGA2 is closely associated with tumor progression, but the role and mechanism of ITGA2 in regulating glioma progression and stemness remain unclear.
Methods
The gene expression profile of GSCs was analyzed by RNA-seq. ITGA2 expression in glioma tissues was examined by immunohistochemical staining, followed by analysis of the correlation between ITGA2 expression and clinical features. In addition, the effects of lentivirus-mediated RNA interference of ITGA2 on cell proliferation, cell migration, spheroid forming ability and cell stemness specific gene and protein expression in glioma cells were investigated.
Results
The expression level of ITGA2 was significantly increased in GSCs compared to glioma cells. ITGA2 protein expression was increased in high-grade glioma samples. Prognostic analysis showed that patients with high ITGA2 expression had shorter survival. In glioma cells, knockdown of ITGA2 significantly inhibited the proliferation, migration, invasion and spheroid forming ability of glioma cells. TCGA data analysis showed that ITGA2 expression positively correlated with the expression of stem cell-specific genes in gliomas. Knockdown of ITGA2 significantly reduced the expression levels of stem cell-specific genes and proteins in the cells. The molecular mechanism revealed that ITGA2 knockdown inhibited the activation of the AKT signaling pathway. The AKT phosphorylation activator SC79 reversed the reduced sphere-forming ability of glioma cells and the reduced expression levels of stem cell-specific genes and proteins in cells caused by ITGA2 knockdown.
Conclusions
Our findings elucidate the role and molecular mechanism of ITGA2 in regulating glioma progression and stemness, and provide new ideas for basic glioma research and tumor treatment strategies targeting GSCs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
586P - Clinical and molecular characteristics of colorectal adenosquamous carcinoma: A multicenter retrospective study
Presenter: Jun Huang
Session: Poster session 16
587P - Homologous recombination (HR) and DNA damage repair (DDR) somatic alterations in metastatic colorectal cancer (mCRC): Results from the comprehensive genomic profiling (CGP) trial FPG500
Presenter: Francesco Schietroma
Session: Poster session 16
588P - Genomic landscape of acquired resistance to first-line (1L) anti-EGFR treatment in metastatic colorectal cancer (mCRC) beyond the classical EGFR pathway: Findings from the PLATFORM-B study
Presenter: Valentino Martelli
Session: Poster session 16
589P - Simultaneous resection versus staged resection for conversion surgery for initially unresectable colorectal liver metastasis: A prospective cohort study
Presenter: Jianmin Xu
Session: Poster session 16
590P - A deep-learning model to predict the completeness of cytoreductive surgery in colorectal cancer with peritoneal metastasis
Presenter: QingFeng Lin
Session: Poster session 16
Resources:
Abstract
591P - Cost-utility of systemic anticancer therapy (SACT) with or without metastasectomy including local ablative therapy (LAT) for metastatic colorectal cancer (mCRC) patients
Presenter: Joel Kontiainen
Session: Poster session 16
592P - Survival analysis of surgical management options for goblet cell adenocarcinoma: Insights from machine learning clustering
Presenter: Marie Line El Asmar
Session: Poster session 16
593P - Treatment response and survival of patients with early onset colorectal cancer in the Netherlands
Presenter: Lauri Borghuis
Session: Poster session 16
594P - Genetic and transcriptomic analyses of Early-Onset Colon Cancer (EOCC): A post-hoc analysis of 2973 patients (pts) from two adjuvant randomized trials
Presenter: Annalice Gandini
Session: Poster session 16
595P - Adoption of remote patient monitoring in gastrointestinal oncology: A real-world experience from 1822 patients across 47 centers in France and Belgium
Presenter: Jerome Desrame
Session: Poster session 16